| abstract |
Abstract of the disclosure: Combination product containing A) on the one hand a pyrimido-pyrimidine of the formula I I in which at least one of the radicals R1 and R3 represents the radical -N(CH2-CHR5-OH)2 where R5 = hydrogen or methyl, and at least one of the radicals R2 and R4 repre-sents the radical which can also be interrupted by oxygen in the p-position relative to the nitrogen atom, or active metabolites and/or salts thereof, and B) on the other hand O-acetylsalicylic acid or pharmaceutically tole-rated salts thereof, the weight ratio of component A) to component B) being greater than 0.5, with or without C) a pharmaceutical vehicle, for sequential administration in the therapy of diseases caused or characterized by impaired blood functions or constituents of blood, in particular platelets or erythrocytes, in a manner such that component A) is released first, its use in human and veterinary medicine, and a process for the preparation of pharmaceu-tical formulations. |